Psychiatry
3 drugs are in development for Major Depressive Disorder.
- Companies
- 3
- Clinical trials
- 48
BioSniper AIPage evidence connected
Prepared research question
Which programs lead the Major Depressive Disorder pipeline—and what evidence could change the picture?
Run cited research
Traceable citations · Unknowns marked
Drug Pipeline by Phase
Phase 3(1)
| Drug | Company |
|---|---|
| rel-1017 | RELMADA THERAPEUTICS, INC. (RLMD) |
Phase 2(2)
| Drug | Company |
|---|---|
| ALTO-300 | Alto Neuroscience, Inc. (ANRO) |
| itruvone | Vistagen Therapeutics, Inc. (VTGN) |
About this indication
Major Depressive Disorder context
Psychiatry·MeSH: Major Depressive Disorder (D003865)
Also known as: Clinical Depression, Depression Disorders, Major, Depressions, Clinical, Depressive Disorders, Major, Major Depression Disorder
Prevalence
5000.0 / 100K
Incidence
300.0 / 100K/yr
Frequently asked questions
How many drugs are in development for Major Depressive Disorder?
BioSniper tracks 3 drugs in development for Major Depressive Disorder across 3 companies.
How many clinical trials target Major Depressive Disorder?
There are 48 clinical trials targeting Major Depressive Disorder tracked by BioSniper.
What is the prevalence of Major Depressive Disorder?
The estimated prevalence of Major Depressive Disorder is approximately 5000.0 per 100,000 population.